Nebu-Flow secures additional investment to accelerate next generation respiratory pharmaceuticals
April 29 2024 - 9:05AM
Business Wire
- The company’s nebulizer platform has been developed to
provide a number of advantages over existing technologies
Nebu-Flow has secured an additional $5.9 million of investment
to accelerate the next generation of inhaled drugs for patients
with respiratory disorders, which are the main cause of death and
disability worldwide. The company’s nebulizer platform has been
developed to provide a number of advantages over existing
technologies. Overall, the worldwide inhalable drug market was
valued at approximately $33 billion in 2023, with the nebulizer
market valued at over $1 billion.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240429118023/en/
Dr Elijah Nazarzadeh (CEO) and Dr John
Pritchard (Chair) of Nebu-Flow (Photo: Business Wire)
The funding round was led by SCVC, a leading UK-based venture
capital firm that invests in early-stage deep tech spinouts, and
was supported by Scottish Enterprise, Foresight WAE Technology, SIS
Ventures, Ascension, and Conduit EIS Impact Fund.
Dr Elijah Nazarzadeh, CEO and co-founder of Nebu-Flow, said:
“Our mission is to revolutionize respiratory drug delivery. The
investment accelerates our development activities to position the
company for inhalation delivery of RNA-based formulations. We now
look forward to the final product development and commercialization
stages, with the support of SCVC and our other investors."
Dr Elijah Nazarzadeh added: “Essentially, our technology
provides new opportunities for targeted drug delivery to the lungs
as well as drug delivery to the cardiovascular and central nervous
systems. We are engaged with a number of partners in the UK and
North America who are currently trialling the product as we prepare
for the regulatory approval stage.”
Dr Harry Destecroix, Managing Partner, SCVC, said: “We are
deeply impressed by the team's achievement of its technical and
commercial milestones to date, demonstrating their capability and
readiness for the next phase in healthcare innovation. This
investment underscores our confidence in Nebu-Flow’s groundbreaking
nebulisation technology, which is poised to transform respiratory
drug delivery, improve health and deliver impact."
Notes:
- Nebu-Flow was recently awarded a £1m project from Innovate UK,
the United Kingdom’s national innovation agency. - Last year, the
former spinout from the University of Glasgow won the Business
Start-up Award from the Institute of Physics for “exceptional
efforts in the application of surface acoustic waves to a new
generation of nebulizers with the potential to transform
respiratory drug delivery”. - Nebu-Flow is featuring at this year’s
Respiratory Drug Delivery Conference, RDD 2024, in Tucson, Arizona
between 5th-9th May. - For more information:
https://www.nebuflow.com/
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240429118023/en/
nick@freerconsultancy.com